nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.09.2014 | original article

Determining the normal range for IGF-I, IGFBP-3, and ALS: new reference data based on current internal standards

verfasst von: Diana-Alexandra Ertl, MD, Andreas Gleiss, PhD, Susanne Sagmeister, Gabriele Haeusler, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2014

Einloggen, um Zugang zu erhalten

Summary

Background

The measurement of insulin-like growth factors (IGF-I) and insulin-like growth factor-binding protein (IGFBP-3) often serves as first-line testing in children with growth disorders. The role of acid-labile subunit (ALS) as a screening parameter for homozygous or heterozygous mutations of the ALS gene still has to be determined.

Methods

IGF-I, IGFBP-3, and ALS were measured in 252 samples from children and adolescents. Reference curves were fitted using generalized additive model for location, scale and shape (GAMLSS) models and SD-Scores were calculated. Bootstrap analysis was used to quantify the uncertainty of the estimated percentiles. Bland-Altman plots were used to investigate the discrepancy between our newly estimated standard deviation scores (SDS) and SDS calculated on the basis of previous reference data.

Results

We present reference data for enzyme-linked immunosorbent assay (ELISA) measurements based on recommended internal standard for IGF-I, IGFBP-3, and ALS suitable for calculation of SD-scores. The Bland-Altman plot shows a rough agreement between the previous SDS calculation and our new one only for SDS around 1; for SDS at − 2, an average difference of 0.83 SD was noticed.

Conclusion

Our IGF-I reference values for the interval of interest in diagnosing growth hormone deficiency (GHD) (prepubertal age) are solid as proved by bootstrap analysis. The difference in calculated SD scores by using data provided previously highlights the importance of using labor and method specific reference data.

Nächster Artikel Osteosarkom – Vertrauenswürdigkeit und Qualität der Informationen im Internet

Le Roith D, Bondy C, Yakar C, Liu J, Butler A. The somatomedin hypothesis. Endocr Rev. 2001;22(1):53–74.PubMedCrossRef

Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. (Epub 2008).PubMedCrossRefPubMedCentral

Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988;67(2):265–72.PubMedCrossRef

Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab. 1993;76(6):1610–6.PubMed

Blum WF, Schweizer R. Insulin-like growth factors and their binding proteins. In Ranke MB, editor. Diagnostics of endocrine function in children and adolescents. Basel: Karger; 2003. p 166–199.CrossRef

Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol. 2001;170(1):63–70.PubMedCrossRef

Domené HM, Hwa V, Jasper HG, Rosenfeld RG. Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab. 2011;25(1):101–13.PubMedCrossRef

Banerjee I, Hanson D, Perveen R, Whatmore A, Black GC, Clayton PE. Constitutional delay of growth and puberty is not commonly associated with mutations in the acid labile subunit gene. Eur J Endocrinol. 2008;158(4):473–7.PubMedCrossRef

David A, Rose S, Miraki-Moud F, Metherell L, Jones J, Edwards R, Camacho-Hubner C, Johnston L, Savage M, Klark A. Heterozygous defect of the acide-labile subunit gene in idiopathic short stature. Horm Res. 2008;70:31

10.

Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebaek NE. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. J Clin Endocrinol Metab. 1998;83(12):4408–15.PubMedCrossRef

11.

Stasinopoulos DM, Rigby RA. Generalized additive models for location scale and shape (GAMLSS) in R. J Stat Softw. 2007;23(7):1–46.

12.

Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135–60.PubMedCrossRef

13.

Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res. 2010;20(1):8–18.PubMedCrossRef

14.

Zapf J, Walter H, Froesch ER. Radioimmunological determination of insulin- like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest. 1981;68(5):1321–30.PubMedCrossRefPubMedCentral

15.

Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr. 1986;109:428–33.PubMedCrossRef

16.

Blum WF, Ranke MB, Bierich JR. A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol (Copenh). 1988;118(3):374–80.

17.

Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990;70(5):1292–8.PubMedCrossRef

18.

Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994;78(3):744–52.PubMed

19.

Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995;80(8):2534–42.PubMed

20.

Bereket A, Turan S, Omar A, Berber M, Ozen A, Akbenlioglu C, Haklar G. Serum IGF-I and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res. 2006;65(2):96–105.PubMedCrossRef

21.

Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 1994;4(Suppl.1):11–9.PubMed

22.

Barrios V, Pozo J, Muñoz MT, Buño M, Argente J. Normative data for total and free acid-labile subunit of the human insulin-like growth factor-binding protein complex in pre- and full-term newborns and healthy boys and girls throughout postnatal development. Horm Res. 2000;53(3):148–53.PubMedCrossRef

23.

Gleiss A, Lassi M, Blümel P, Borkenstein M, Kapelari K, Mayer M, Schemper M, Häusler G. Austrian height and body proportion references for children aged 4 to under 19 years. Ann Hum Biol. 2013;40(4):324–32.PubMedCrossRef

24.

Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf). 2000;53(3):329–36.CrossRef

25.

Ridder M, Stijen T, Hokken-Koelega A. Prediction of adult height in growth hormone- treated children with growth hormone deficiency. J Clin Endocrinol Metab. 2007;92(3):925–31.PubMedCrossRef

26.

http://www.ema.europa.eu/ema/index.jsp?curl=/pages/news_and_events/news/2010/12/news_detail_001160.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1

27.

Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–25.PubMedCrossRef

28.

Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):213–7.CrossRef

29.

Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah growth study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994;125:29–35.PubMedCrossRef

30.

Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW. Prevalence of severe growth hormone deficiency. BMJ. 1977;13:427–30.CrossRef

31.

Thomas M, Massa G, Craen M, de Zegher F, Bourguignon JP, Heinrichs C, De Schepper J, Du Caj M, Thiry-Counson G, Maes M. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986–2001. Eur J Endocrinol. 2004;151:67–72.PubMedCrossRef

32.

Ranke MB, Wölfle J, Schnabel D, Bettendorf M. Behandlung des Kleinwuchses mit rekombinantem humanem “Insulin-like Growth Factor-1”. Deutsches Ärzteblatt. 2009;Jg. 106(43):703–9.

33.

Juul A, Flyvbjerg A, Frystyk J, Müller J, Skakkebaek NE. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins –1 and –3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endocrinol (Oxf). 1996;44(5):515–23.CrossRef

34.

Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Müller J, Skakkebaek NE. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab. 1997;82(8):2497–502.PubMed

35.

Kawai N, Kanzaki S, Takano-Watou S, Tada C, Yamanaka Y, Miyata T, Oka M, Seino YJ. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency. Clin Endocrinol Metab. 1999;84(1):82–9.

36.

Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab. 2001;86(12):5870–6.PubMedCrossRef

37.

Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthén L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P. German KIMS Board. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res. 2003;60(2):53–60.PubMedCrossRef

38.

Elmlinger MW, Kühnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 2004;42(6):654–64.PubMedCrossRef

39.

Löfqvist C, Andersson E, Gelander L, Rosberg S, Hulthen L, Blum WF, Wikland KA. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab. 2005;90(3):1420–7.PubMedCrossRef

40.

Xu S, Gu X, Pan H, Zhu H, Gong F, Li Y, Xing Y. Reference ranges for serum IGF-1 and IGFBP-3 levels in Chinese children during childhood and adolescence. Endocr J. 2010;57(3):221–8.PubMedCrossRef

Titel: Determining the normal range for IGF-I, IGFBP-3, and ALS: new reference data based on current internal standards
verfasst von: Diana-Alexandra Ertl, MD
Andreas Gleiss, PhD
Susanne Sagmeister
Gabriele Haeusler, MD, PhD
Publikationsdatum: 01.09.2014
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 17-18/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-014-0299-4

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2014

Bullöses Pemphigoid – Diagnostik und Therapie

Benign chondroid syringoma (mixed tumor of skin) on the flank with satellites: case report and literature review

Möglichkeiten und Grenzen der forensischen Blutspurenmusterverteilungsanalyse

Osteosarkom – Vertrauenswürdigkeit und Qualität der Informationen im Internet

62-jähriger Patient mit lageabhängiger Dyspnoe nach einseitiger Pneumektomie